<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccine</journal-id><journal-id journal-id-type="iso-abbrev">Vaccine</journal-id><journal-id journal-id-type="pmc-domain-id">3815</journal-id><journal-id journal-id-type="pmc-domain">pheelsevier</journal-id><journal-title-group><journal-title>Vaccine</journal-title></journal-title-group><issn pub-type="ppub">0264-410X</issn><issn pub-type="epub">1873-2518</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Elsevier - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7837099</article-id><article-id pub-id-type="pmcid-ver">PMC7837099.1</article-id><article-id pub-id-type="pmcaid">7837099</article-id><article-id pub-id-type="pmcaiid">7837099</article-id><article-id pub-id-type="pmid">32684497</article-id><article-id pub-id-type="doi">10.1016/j.vaccine.2020.07.003</article-id><article-id pub-id-type="pii">S0264-410X(20)30903-8</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name name-style="western"><surname>Hashemzadeh</surname><given-names initials="A">Alireza</given-names></name><xref rid="af005" ref-type="aff">a</xref><xref rid="af010" ref-type="aff">b</xref><xref rid="af015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au010"><name name-style="western"><surname>Avan</surname><given-names initials="A">Amir</given-names></name><xref rid="af010" ref-type="aff">b</xref><xref rid="af015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au015"><name name-style="western"><surname>Ferns</surname><given-names initials="GA">Gordon A.</given-names></name><xref rid="af020" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au020"><name name-style="western"><surname>Khazaei</surname><given-names initials="M">Majid</given-names></name><xref rid="af005" ref-type="aff">a</xref><xref rid="af015" ref-type="aff">c</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><aff id="af005"><label>a</label>Department of Medical Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</aff><aff id="af010"><label>b</label>Department of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</aff><aff id="af015"><label>c</label>Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</aff><aff id="af020"><label>d</label>Brighton &amp; Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author at: Metabolic syndrome Research center, Mashhad University of Medical Sciences, Mashhad, Iran.</corresp></author-notes><pub-date pub-type="ppub"><day>10</day><month>8</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>11</day><month>7</month><year>2020</year></pub-date><volume>38</volume><issue>36</issue><issue-id pub-id-type="pmc-issue-id">373807</issue-id><fpage>5742</fpage><lpage>5746</lpage><history><date date-type="received"><day>11</day><month>4</month><year>2020</year></date><date date-type="rev-recd"><day>1</day><month>7</month><year>2020</year></date><date date-type="accepted"><day>2</day><month>7</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>11</day><month>07</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>26</day><month>01</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-27 00:25:12.663"><day>27</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2020 Published by Elsevier Ltd.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder/><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="ab005"><p>Recent advances in virus-like nanoparticles against Middle East respiratory syndrome-related coronavirus (MERS-CoV) can initiate vaccine production faster for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), while ensuring the safety, easy administration, and long-term effects. Patients with this viral pathogen suffer from excess mortality. MERS-CoV can spread through bioaerosol transmission from animal or human sources. The appearance of an outbreak in South Korea sparked off a strong urge to design strategies for developing an effective vaccine since the emergence of MERS-CoV in 2012. Well unfortunately, this is an important fact in virus risk management. The studies showed that virus-like nanoparticles (VLPs) could be effective in its goal of stopping the symptoms of MERS-CoV infection. Besides, due to the genetic similarities in the DNA sequencing of SARS-CoV-2 with MERS-CoV and the first identified severe acute respiratory syndrome (SARS-CoV) in China since 2002/2003, strategic approaches could be used to manage SARS-CoV 2. Gathering the vital piece of information obtained so far could lead to a breakthrough in the development of an effective vaccine against SARS-CoV-2, which is prioritized and focussed by the World Health Organization (WHO). This review focuses on the virus-like nanoparticle that got successful results in animal models of MERS-CoV.</p></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>MERS-CoV</kwd><kwd>Coronavirus</kwd><kwd>Vaccine</kwd><kwd>Virus-like particles</kwd><kwd>Nanoparticles</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0005">The Middle East respiratory syndrome (MERS) is a highly infectious viral disease that first appeared in 2012 at Saudi Arabia, originally crossing the species barrier from camels to humans, and an outbreak caused many deaths in South Korea <xref rid="b0005" ref-type="bibr">[1]</xref>, <xref rid="b0010" ref-type="bibr">[2]</xref>, <xref rid="b0015" ref-type="bibr">[3]</xref>, <xref rid="b0020" ref-type="bibr">[4]</xref>. The high mortality of MERS-related coronavirus (MERS-CoV) was &#8776;35%, led the World Health Organization to the conclusion that employing effective countermeasures like vaccination were needed to reduce MERS-CoV epidemic impact <xref rid="b0025" ref-type="bibr">[5]</xref>, <xref rid="b0030" ref-type="bibr">[6]</xref>. In vaccine production, a major limiting factor in designing comprehensive delivery systems for aerosol transmissible diseases is the enhancement of efficacy and easy vaccine administration <xref rid="b0005" ref-type="bibr">[1]</xref>, <xref rid="b0035" ref-type="bibr">[7]</xref>. Extensive information on transmission, pathogenesis, and epidemiology of MERS-CoV is needed in both humans and animals to facilitate the development of a new vaccine <xref rid="b0040" ref-type="bibr">[8]</xref>. Recently, the focus is concentrated on MERS-CoV spike (S) protein, a viral surface glycoprotein, providing the basis for the synthesis of virus-like particles (VLPs) <xref rid="b0040" ref-type="bibr">[8]</xref>. Vaccines based on antibodies, DNA <xref rid="b0045" ref-type="bibr">[9]</xref>, adenoviruses, vectors <xref rid="b0050" ref-type="bibr">[10]</xref>, <xref rid="b0055" ref-type="bibr">[11]</xref>, antigen and adjuvant delivery have shown potentially promising results and may support future developments based on virus-mimicking behavior. Synthetic vaccines for MERS-CoV utilizing potent antigens in combination of proper adjuvant could increase the potency of the prepared vaccine <xref rid="b0060" ref-type="bibr">[12]</xref>. In this manner, the nanoscale morphology that is very similar to that of a native MERS-CoV virus <xref rid="b0065" ref-type="bibr">[13]</xref> with consideration of sequenced delivery of antigen and adjuvant <xref rid="b0070" ref-type="bibr">[14]</xref> could enhance the immunogenicity and promote danger signals that mimic the authentic MERS-CoV virus.</p><p id="p0010">The S protein of MERS-CoV is an essential component of the immunogenic vaccines of the future with the advantage of facilitating virus attachment step via Human Dipeptidyl Peptidase 4 (hDPP4) <xref rid="b0075" ref-type="bibr">[15]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0090" ref-type="bibr">[18]</xref>. In the current outbreak, severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) uses its S proteins to bound to the angiotensin-converting enzyme 2 and enter the cells with affinities of at least 10 time more severe than acute respiratory syndrome (SARS) <xref rid="b0095" ref-type="bibr">[19]</xref>. Novavax (USA) designed a virus-like particle (VLP) from MERS-CoV S protein that induced neutralizing antibodies and enhanced the immune response after one injection in a mice model <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>. The synthesis of VLPs in vaccine technology is a novel strategic approach to developing new and more effective vaccines <xref rid="b0110" ref-type="bibr">[22]</xref>. Using appropriate design of VLPs by S protein of SARS-CoV-2 and proper adjuvants can also stimulate the immune system of the body to produce countermeasures that are more effective. The present review further explores the concept of virus mimicking nanoparticles and the development of nanoparticle vaccines against MERS-CoV. The genetic sequence of SARS-COV 2 is closely related to the MERS-CoV and SARS-CoV <xref rid="b0115" ref-type="bibr">[23]</xref>, hence, the information obtained from their vaccine advancement efforts could help to progress the development cycle of SARS-CoV-2 vaccine. Herein, this review focuses on the virus-based nano-formulations that have successful results in animal models of MERS-CoV in the hope finding a more effective approach to manage these epidemic diseases.</p></sec><sec id="s0010"><label>2</label><title>Advantages of nanoparticle-based vaccine</title><p id="p0015">Nanoparticles designed to mimic viruses with engineered nanoscale morphology <xref rid="b0065" ref-type="bibr">[13]</xref>, multivalent antigens <xref rid="b0120" ref-type="bibr">[24]</xref>, and colonizing antigens/adjuvants (danger signals); using a single nanoparticle may promote immune responses via antigen processing and immune system engagement <xref rid="b0070" ref-type="bibr">[14]</xref>. Nanoscale VLPs with viral characteristics are transported better through the lymphatics and capillaries in comparison with smaller subunit vaccines <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0125" ref-type="bibr">[25]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>. This improves cellular uptake and reduces the systemic inflammatory response <xref rid="b0130" ref-type="bibr">[26]</xref>. Besides, the ability to deliver multiple antigens promotes antigen-presenting cell or accessory cells to function more effectively, hence, T cell receptors can recognize the synthesized complexes that increase immunogenicity and potency of the vaccine, which could protect the safety and welfare of the patients <xref rid="b0125" ref-type="bibr">[25]</xref>. Innate immune system activation and better cellular uptake of VLPs, consisting of recombinant viral antigens and adjuvants, can enhance the effects of the complement cascade to attack pathogens and the presentation to follicular dendritic cells, which lead to B cell activation and potentiation of the immune system by inducing proactive immune responses against viral infections <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>. In fact, synthetic nano VLPs elicit virus-like characteristics and evoke immune responses against viral infections, which is an essential aspect of vaccine design, development, and future disease management <xref rid="b0145" ref-type="bibr">[29]</xref>, <xref rid="b0150" ref-type="bibr">[30]</xref>, <xref rid="b0155" ref-type="bibr">[31]</xref>, <xref rid="b0160" ref-type="bibr">[32]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>. Another advantage is the formation of protein corona around the synthetic nanoparticles via surface passivation that, at first glance, prevents agglomeration and increases the size especially in inorganic nanostructures, but promotes the innovative design of complex vaccines using nanocarriers and proteins via Van der Waals and covalent interactions <xref rid="b0175" ref-type="bibr">[35]</xref>, <xref rid="b0180" ref-type="bibr">[36]</xref>, <xref rid="b0185" ref-type="bibr">[37]</xref>, <xref rid="b0190" ref-type="bibr">[38]</xref>, <xref rid="b0195" ref-type="bibr">[39]</xref>, <xref rid="b0200" ref-type="bibr">[40]</xref>. For instance, VLPs based on inorganic gold nanoparticles have higher surface energy than their organic counterparts, which interact strongly with biomolecules, antigens, and adjuvants, through weak electric forces such as Van der Waals force and dipole&#8211;dipole interaction, or covalent bond <xref rid="b0190" ref-type="bibr">[38]</xref>, <xref rid="b0205" ref-type="bibr">[41]</xref>.</p></sec><sec id="s0015"><label>3</label><title>Spike protein of MERS-CoV</title><p id="p0020">The immunogenic MERS-CoV proteins include Spike (S), membrane (M) and envelope (E). Among them, the S protein mediates viral entry into the host cells <xref rid="b0210" ref-type="bibr">[42]</xref>; accordingly, the S protein can be used as the principal targeting agent against MERS-CoV, because of having the ability to build the developing strategies for new generation of virus-mimicking vaccines. <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0215" ref-type="bibr">[43]</xref>, <xref rid="b0220" ref-type="bibr">[44]</xref>. The S protein could self-assemble into a crown-like nanoparticle with about 25&#160;nm in diameter, in which the size was reduced to about one-quarter of MERS-CoV, and could trigger cell attachment, including fusion and cellular binding <xref rid="b0225" ref-type="bibr">[45]</xref>, <xref rid="b0230" ref-type="bibr">[46]</xref>. In an animal model, the potential of S proteins to stimulate immune responses is confirmed in the presence of alum induced neutralizing antibodies <xref rid="b0100" ref-type="bibr">[20]</xref>. The S glycoprotein has two subunits, S1 and S2. The S1 subunit binds to the hDPP4 receptor, and the S2 subunit is involved in membrane fusion (virus-cell fusion) <xref rid="b0235" ref-type="bibr">[47]</xref>. Some neutralizing antibodies deactivate the S1 subunit, receptor-binding domain (RBD), by blocking the interaction with hDPP4, and this could be a principal target in the vaccine development of MERS-CoV <xref rid="b0240" ref-type="bibr">[48]</xref>, <xref rid="b0245" ref-type="bibr">[49]</xref>, <xref rid="b0250" ref-type="bibr">[50]</xref>, <xref rid="b0255" ref-type="bibr">[51]</xref>, <xref rid="b0260" ref-type="bibr">[52]</xref>, <xref rid="b0265" ref-type="bibr">[53]</xref>, <xref rid="b0270" ref-type="bibr">[54]</xref>, <xref rid="b0275" ref-type="bibr">[55]</xref>. Recently, Th1 mediated immunity was seen after induction of virus-neutralizing antibodies after immunization of macaca mulatta by an S protein based VLP against MERS-CoV <xref rid="b0210" ref-type="bibr">[42]</xref>. VLPs based on S protein also showed a Th1 and Th2 mediated immunity in mice primed with rAd5-vector <xref rid="b0280" ref-type="bibr">[56]</xref>.</p></sec><sec id="s0020"><label>4</label><title>Vaccines based on Virus-like Particles (VLPs)</title><p id="p0025">High levels of an immunogenically active drug may lead to inflammatory and excessive immunological responses. Therefore, safety precautions and new formulations may be needed to reduce the side effects <xref rid="b0155" ref-type="bibr">[31]</xref>, <xref rid="b0285" ref-type="bibr">[57]</xref>, <xref rid="b0290" ref-type="bibr">[58]</xref>. Nanoscale vaccines based on calcium phosphate nanobioceramics <xref rid="b0295" ref-type="bibr">[59]</xref>, liposomes <xref rid="b0150" ref-type="bibr">[30]</xref>, <xref rid="b0300" ref-type="bibr">[60]</xref>, polymer-based microparticles <xref rid="b0305" ref-type="bibr">[61]</xref>, <xref rid="b0310" ref-type="bibr">[62]</xref>, cationic polymers <xref rid="b0315" ref-type="bibr">[63]</xref>, <xref rid="b0320" ref-type="bibr">[64]</xref>, virus-like nanoparticles (VLPs) <xref rid="b0325" ref-type="bibr">[65]</xref>, nanoparticle assemblies from multimeric peptides <xref rid="b0330" ref-type="bibr">[66]</xref>, <xref rid="b0335" ref-type="bibr">[67]</xref> and gold nanoparticles <xref rid="b0205" ref-type="bibr">[41]</xref>, <xref rid="b0340" ref-type="bibr">[68]</xref> could target the lymphatic system and would improve safety and efficacy. In addition, the mentioned structures are amenable for modifications that may increase the biocompatibility, lead to size control, stability, and controlled antigen/adjuvant loading and release.</p><p id="p0030">VLPs are widely used in vaccines as carriers and are comparable to subunit vaccines, in which a viral protein is generated <xref rid="b0345" ref-type="bibr">[69]</xref>, <xref rid="b0350" ref-type="bibr">[70]</xref>, <xref rid="b0355" ref-type="bibr">[71]</xref>, <xref rid="b0360" ref-type="bibr">[72]</xref>. VLPs are recombinant forms of viral proteins and adjuvants with the potential for developing a self-assembled structure. They can act as an adjuvant due to their small size and give rise to the potential immunogenic epitopes that produce higher immunogenicity. Other adjuvants could also be used to cause greater immune responses in comparison with the virus <xref rid="b0210" ref-type="bibr">[42]</xref>, <xref rid="b0365" ref-type="bibr">[73]</xref>, <xref rid="b0370" ref-type="bibr">[74]</xref>. The designed vaccines have used recombinant forms or viral proteins including S, S1, or RBD, and vector or DNA based adjuvants against MERS-CoV infection (<xref rid="t0005" ref-type="table">Table 1</xref>
). Animals vaccinated with VLPs were shown to effectively overcome the virus due to an increased immune response <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0245" ref-type="bibr">[49]</xref>, <xref rid="b0375" ref-type="bibr">[75]</xref>.<table-wrap position="float" id="t0005" orientation="portrait"><label>Table 1</label><caption><p>Designed VLPs against MERS-CoV.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Treatment</th><th colspan="1" rowspan="1">Responses</th><th colspan="1" rowspan="1">Animal model</th><th colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">rAd5-S protein and alum-adjuvanted recombinant S protein</td><td colspan="1" rowspan="1">Mixed Th1/Th2 immune responses, heterologous prime&#8211;boost</td><td colspan="1" rowspan="1">SPF BALB/c mice</td><td colspan="1" rowspan="1"><xref rid="b0280" ref-type="bibr">[56]</xref></td></tr><tr><td colspan="1" rowspan="1">S protein VLP in the presence of alum</td><td colspan="1" rowspan="1">Induction of neutralizing antibody</td><td colspan="1" rowspan="1">BALB/c mice</td><td colspan="1" rowspan="1"><xref rid="b0100" ref-type="bibr">[20]</xref></td></tr><tr><td colspan="1" rowspan="1">A recombinant form of MERS-CoV S protein with Matrix-M1adjuvant</td><td colspan="1" rowspan="1">Stimulation of neutralizing antibody</td><td colspan="1" rowspan="1">BALB/c mice</td><td colspan="1" rowspan="1"><xref rid="b0380" ref-type="bibr">[76]</xref></td></tr><tr><td colspan="1" rowspan="1">poly(c-di-GMP inside lactic-co-glycolicacid) with MERS-CoV RBD antigens</td><td colspan="1" rowspan="1">elicitation of neutralization antibody, antigen-specific T cell responses, an inducer of type I interferons</td><td colspan="1" rowspan="1">C57/BL6 mice (DPP4-transgenic)</td><td colspan="1" rowspan="1"><xref rid="b0025" ref-type="bibr">[5]</xref></td></tr><tr><td colspan="1" rowspan="1">cVLP of CPV VP2 structural protein with the MERS-CoV RBD in presence of Alum and poly(I:C) adjuvants</td><td colspan="1" rowspan="1">Mixed Th1/Th2 immunity, elicited neutralizing antibody, induction of B- and T-cell, IFN-&#947; induction</td><td colspan="1" rowspan="1">BALB/c mice</td><td colspan="1" rowspan="1"><xref rid="b0385" ref-type="bibr">[77]</xref></td></tr><tr><td colspan="1" rowspan="1">cVLP of CPV VP2 structural protein with the MERS-CoV RBD</td><td colspan="1" rowspan="1">B- and T-cell induction, mixed Th1 and Th2 responses, expression of IFN-&#945;/&#946;</td><td colspan="1" rowspan="1">rhesus macaques</td><td colspan="1" rowspan="1"><xref rid="b0390" ref-type="bibr">[78]</xref></td></tr><tr><td colspan="1" rowspan="1">VLP obtained from a polyclonal immunoglobulin G (IgG) antibody and a clade B S protein</td><td colspan="1" rowspan="1">High neutralizing antibody titers, passive immunotherapy, robust immune response</td><td colspan="1" rowspan="1">BALB/c mice (Ad5-hDPP4&#8211;transduced)</td><td colspan="1" rowspan="1"><xref rid="b0395" ref-type="bibr">[79]</xref></td></tr><tr><td colspan="1" rowspan="1">VLP obtained from MERS-CoV RBD protein and bacterioferritin</td><td colspan="1" rowspan="1">interfere with the binding to the hDPP4 receptor and immune responses by the assembly of antigens</td><td colspan="1" rowspan="1">BALB/c mice</td><td colspan="1" rowspan="1"><xref rid="b0400" ref-type="bibr">[80]</xref></td></tr></tbody></table></table-wrap></p><p id="p0035">Recently, silkworm larvae have been used to generate the S protein of MERS-CoV, which was then used to prepare nanovesicles <xref rid="b0210" ref-type="bibr">[42]</xref> by surfactant treatment <xref rid="b0405" ref-type="bibr">[81]</xref> and mechanical extrusion <xref rid="b0410" ref-type="bibr">[82]</xref>, <xref rid="b0415" ref-type="bibr">[83]</xref>. Recombinant proteins of S, E and M were used to synthesize MERS-CoV VLPs, tested in an animal model and were associated with greater immunogenicity <xref rid="b0210" ref-type="bibr">[42]</xref>. Nanoparticles derived from rAd5-S protein with alum mediated neutralizing antibodies showed a successful immune response against MERS-CoV, tested in vivo using specific pathogen-free BALB/c mice, which increased Th1 and Th2 immunogenicity <xref rid="b0280" ref-type="bibr">[56]</xref>. In another study, nanoparticle was fromed a recombinant of SAB-301, a polyclonal immunoglobulin G (IgG) antibody, and a clade B S protein that lowered the MERS-CoV infection below the in vivo detection limits <xref rid="b0395" ref-type="bibr">[79]</xref>. The VLP vaccine platform engineered by employing the recombinant E protein of another virus could produce a chimeric VLP (cVLP), in which different epitopes trigger the cell attachment to different antibodies <xref rid="b0420" ref-type="bibr">[84]</xref>. For instance, the structural protein of canine parvovirus (CPV), VP2, was fused with the MERS-COV RBD, generating a cVLP that could increase the immune responses in mice <xref rid="b0385" ref-type="bibr">[77]</xref>. The recombinant form of S protein of MERS-CoV and influenza A virus M1 protein also showed greater immunogenicity in a mouse model <xref rid="b0425" ref-type="bibr">[85]</xref>. Nanoparticles from the recombinant form MERS-CoV S protein and M1 protein prevented the virus replication in the lungs of the vaccinated mice <xref rid="b0240" ref-type="bibr">[48]</xref>, <xref rid="b0430" ref-type="bibr">[86]</xref>, <xref rid="b0435" ref-type="bibr">[87]</xref>, <xref rid="b0440" ref-type="bibr">[88]</xref>. Aggregations of viral antigens due to protein misfolding may lead to the lower solubility of VLPs. RNA as a molecular chaperone was used as a folding agent and subsequently, it was fused with the RBD of MERS-CoV. The sera that was separated after immunization of the mouse with the synthetic VLP, showed the blockage of the binding site to hDPP4 of MERS-CoV RBD <xref rid="b0005" ref-type="bibr">[1]</xref>.</p><p id="p0040">Enzymes such as viral proteases encoded by DNA or RNA of the virus or signaling proteins like interferons could be implemented to increase the immunogenicity of the prepared vaccines. Reports showed MERS-CoV uses the protein-coding genes of the host cell, including TMPRSS2 (Transmembrane Serine Protease 2), FURIN (paired basic amino acid cleaving enzyme) and cathepsins, to facilitate virus-cell fusion <xref rid="b0445" ref-type="bibr">[89]</xref>, <xref rid="b0450" ref-type="bibr">[90]</xref>, <xref rid="b0455" ref-type="bibr">[91]</xref>. The presence of a subgroup of interferons, Human type I interferons (IFNs) as an important mediator of the innate immune system could also effective against MERS-CoV. It seems that viral replication and transmission of MERS-CoV was prevented by controlling the previously mentioned cell proteases and the presence of cytokines of the innate immune system <xref rid="b0445" ref-type="bibr">[89]</xref>, <xref rid="b0450" ref-type="bibr">[90]</xref>, <xref rid="b0455" ref-type="bibr">[91]</xref>, <xref rid="b0460" ref-type="bibr">[92]</xref>, <xref rid="b0465" ref-type="bibr">[93]</xref>, <xref rid="b0470" ref-type="bibr">[94]</xref>. IFN signaling is effective after antigen presentation; otherwise, it suppresses the innate immune system <xref rid="b0150" ref-type="bibr">[30]</xref>, <xref rid="b0310" ref-type="bibr">[62]</xref>, <xref rid="b0475" ref-type="bibr">[95]</xref>. Therefore, the sequencing of the release mechanism and timing affect the results. The optimal arrangement of the antigen and adjuvant should be taken into consideration in the engineered nanoparticle vaccines <xref rid="b0480" ref-type="bibr">[96]</xref>, <xref rid="b0485" ref-type="bibr">[97]</xref>, <xref rid="b0490" ref-type="bibr">[98]</xref>. The stimulator of interferon genes (STING) agonists combined with antigen presentation could also activate adaptive immunity <xref rid="b0495" ref-type="bibr">[99]</xref>, <xref rid="b0500" ref-type="bibr">[100]</xref>, <xref rid="b0505" ref-type="bibr">[101]</xref>. The synthetic hollow VLPs (hVLPs) have the advantage of encapsulating cargoes that are tailored to meet the timing and dosing requirements using recombinant viral antigens <xref rid="b0025" ref-type="bibr">[5]</xref>. The mouse immunized with a hollow VLP, composed of a polymeric hollow nanoparticle, RBD antigen and STING agonist, was capable of promoting long-lasting T cells and Th1/Th2 immune responses. The mechanism of action was similar to other STING mediated stimulations and led to generation protective neutralizing antibodies against MERS-CoV <xref rid="b0025" ref-type="bibr">[5]</xref>, <xref rid="b0495" ref-type="bibr">[99]</xref>, <xref rid="b0510" ref-type="bibr">[102]</xref>.</p></sec><sec id="s0025"><label>5</label><title>Conclusion</title><p id="p0045">Advances in virus-like nanoparticles against MERS-CoV could help to adopt some basic information against SARS-CoV 2. VLPs are flexible and can be designed for specific aims, for example, to increase vaccine safety and efficacy. Wise recombinant of a subunit antigen and an adjuvant can heighten the innate and adaptive immune responses. It seems timing in adjuvant and antigen release could greatly influence the effectiveness. As this review represents, the nano-engineering of viral proteins could open a new horizon for the preparation of an effective MERS-CoV vaccine.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="p0050">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><label>1</label><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Son</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bin Kwon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Chaperna-mediated assembly of ferritin-based Middle East respiratory syndrome-coronavirus nanoparticles</article-title><source>Front Immunol</source><volume>9</volume><year>2018</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.01093</pub-id><pub-id pub-id-type="pmcid">PMC5966535</pub-id><pub-id pub-id-type="pmid">29868035</pub-id></element-citation></ref><ref id="b0010"><label>2</label><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name name-style="western"><surname>Breban</surname><given-names>R.</given-names></name><name name-style="western"><surname>Riou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fontanet</surname><given-names>A.</given-names></name></person-group><article-title>Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk</article-title><source>The Lancet</source><volume>382</volume><year>2013</year><fpage>694</fpage><lpage>699</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(13)61492-0</pub-id><pub-id pub-id-type="pmcid">PMC7159280</pub-id><pub-id pub-id-type="pmid">23831141</pub-id></element-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>J.Y.</given-names></name></person-group><article-title>An outbreak of Middle East respiratory syndrome coronavirus infection in South Korea, 2015</article-title><source>Yonsei Med J</source><volume>56</volume><year>2015</year><fpage>1174</fpage><lpage>1176</lpage><pub-id pub-id-type="pmid">26256957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3349/ymj.2015.56.5.1174</pub-id><pub-id pub-id-type="pmcid">PMC4541644</pub-id></element-citation></ref><ref id="b0020"><label>4</label><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name name-style="western"><surname>Ki</surname><given-names>M.</given-names></name></person-group><article-title>2015 MERS outbreak in Korea: hospital-to-hospital transmission</article-title><source>Epidemiol Health</source><volume>37</volume><year>2015</year><fpage>e2015033</fpage><pub-id pub-id-type="pmid">26212508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4178/epih/e2015033</pub-id><pub-id pub-id-type="pmcid">PMC4533026</pub-id></element-citation></ref><ref id="b0025"><label>5</label><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>L.C.W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>B.Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Algaissi</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Viromimetic STING agonist-loaded hollow polymeric nanoparticles for safe and effective vaccination against middle east respiratory syndrome coronavirus</article-title><source>Adv Funct Mater</source><volume>29</volume><year>2019</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adfm.201807616</pub-id><pub-id pub-id-type="pmcid">PMC7161765</pub-id><pub-id pub-id-type="pmid">32313544</pub-id></element-citation></ref><ref id="b0030"><label>6</label><element-citation publication-type="book" id="h0030"><person-group person-group-type="author"><name name-style="western"><surname>Organization</surname><given-names>W.H.</given-names></name></person-group><part-title>WHO MERS-CoV global summary and assessment of risk</part-title><year>2017</year><publisher-name>WHO</publisher-name><publisher-loc>Geneva</publisher-loc></element-citation></ref><ref id="b0035"><label>7</label><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>R.Z.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Chao</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Shieh</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Chuang</surname><given-names>K.P.</given-names></name></person-group><article-title>Innovation of a new virus-like nanoparticle vaccine system for the specific aerosol relative disease</article-title><source>Aerosol Air Qual Res</source><volume>16</volume><year>2016</year><fpage>2421</fpage><lpage>2427</lpage></element-citation></ref><ref id="b0040"><label>8</label><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name name-style="western"><surname>Excler</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Delvecchio</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Wiley</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>I.K.</given-names></name><name name-style="western"><surname>Modjarrad</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Toward developing a preventive MERS-CoV vaccine-report from a workshop organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14&#8211;15, 2015</article-title><source>Emerg Infect Dis</source><volume>22</volume><year>2016</year><fpage>E1</fpage><lpage>E7</lpage><pub-id pub-id-type="pmid">27439020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid2208.160229</pub-id><pub-id pub-id-type="pmcid">PMC4982192</pub-id></element-citation></ref><ref id="b0045"><label>9</label><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name name-style="western"><surname>Muthumani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Falzarano</surname><given-names>D.</given-names></name><name name-style="western"><surname>Reuschel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tingey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Flingai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Villarreal</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates</article-title><source>Sci Transl Med</source><volume>7</volume><year>2015</year><fpage>301ra132</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aac7462</pub-id><pub-id pub-id-type="pmcid">PMC4573558</pub-id><pub-id pub-id-type="pmid">26290414</pub-id></element-citation></ref><ref id="b0050"><label>10</label><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name name-style="western"><surname>Alharbi</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Padron-Regalado</surname><given-names>E.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Kupke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sloan</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice</article-title><source>Vaccine</source><volume>35</volume><year>2017</year><fpage>3780</fpage><lpage>3788</lpage><pub-id pub-id-type="pmid">28579232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2017.05.032</pub-id><pub-id pub-id-type="pmcid">PMC5516308</pub-id></element-citation></ref><ref id="b0055"><label>11</label><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name name-style="western"><surname>Haagmans</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>van den Brand</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Raj</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Volz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wohlsein</surname><given-names>P.</given-names></name><name name-style="western"><surname>Smits</surname><given-names>S.L.</given-names></name><etal/></person-group><article-title>An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels</article-title><source>Science</source><volume>351</volume><year>2016</year><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">26678878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aad1283</pub-id></element-citation></ref><ref id="b0060"><label>12</label><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>L.C.W.</given-names></name><name name-style="western"><surname>Chattopadhyay</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C.M.J.</given-names></name></person-group><article-title>Advances and opportunities in nanoparticle-and nanomaterial-based vaccines against bacterial infections</article-title><source>Adv Healthcare Mater</source><volume>7</volume><year>2018</year><fpage>1701395</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.201701395</pub-id><pub-id pub-id-type="pmid">29508547</pub-id></element-citation></ref><ref id="b0065"><label>13</label><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>van der Vlies</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Simeoni</surname><given-names>E.</given-names></name><name name-style="western"><surname>Angeli</surname><given-names>V.</given-names></name><name name-style="western"><surname>Randolph</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>O'Neil</surname><given-names>C.P.</given-names></name><etal/></person-group><article-title>Exploiting lymphatic transport and complement activation in nanoparticle vaccines</article-title><source>Nat Biotechnol</source><volume>25</volume><year>2007</year><fpage>1159</fpage><lpage>1164</lpage><pub-id pub-id-type="pmid">17873867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt1332</pub-id></element-citation></ref><ref id="b0070"><label>14</label><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name name-style="western"><surname>Blander</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Medzhitov</surname><given-names>R.</given-names></name></person-group><article-title>Toll-dependent selection of microbial antigens for presentation by dendritic cells</article-title><source>Nature</source><volume>440</volume><year>2006</year><fpage>808</fpage><lpage>812</lpage><pub-id pub-id-type="pmid">16489357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature04596</pub-id></element-citation></ref><ref id="b0075"><label>15</label><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name name-style="western"><surname>Raj</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Mou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Smits</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Dekkers</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Dijkman</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC</article-title><source>Nature</source><volume>495</volume><year>2013</year><fpage>251</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">23486063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature12005</pub-id><pub-id pub-id-type="pmcid">PMC7095326</pub-id></element-citation></ref><ref id="b0080"><label>16</label><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name name-style="western"><surname>Buchholz</surname><given-names>U.J.</given-names></name><name name-style="western"><surname>Bukreyev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lamirande</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity</article-title><source>Proc Natl Acad Sci</source><volume>101</volume><year>2004</year><fpage>9804</fpage><lpage>9809</lpage><pub-id pub-id-type="pmid">15210961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0403492101</pub-id><pub-id pub-id-type="pmcid">PMC470755</pub-id></element-citation></ref><ref id="b0085"><label>17</label><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Poon</surname><given-names>V.K.</given-names></name><etal/></person-group><article-title>Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development</article-title><source>J Virol</source><volume>87</volume><year>2013</year><fpage>9939</fpage><lpage>9942</lpage><pub-id pub-id-type="pmid">23824801</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01048-13</pub-id><pub-id pub-id-type="pmcid">PMC3754113</pub-id></element-citation></ref><ref id="b0090"><label>18</label><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name name-style="western"><surname>Shehata</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Mostafa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Teubner</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mahmoud</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Kandeil</surname><given-names>A.</given-names></name><name name-style="western"><surname>Elshesheny</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Bacterial outer membrane vesicles (omvs)-based dual vaccine for influenza a h1n1 virus and mers-cov</article-title><source>Vaccines</source><volume>7</volume><year>2019</year><fpage>46</fpage><pub-id pub-id-type="pmid">31141982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines7020046</pub-id><pub-id pub-id-type="pmcid">PMC6631769</pub-id></element-citation></ref><ref id="b0095"><label>19</label><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name name-style="western"><surname>Wrapp</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Corbett</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>C.-L.</given-names></name><name name-style="western"><surname>Abiona</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><volume>367</volume><year>2020</year><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="pmid">32075877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abb2507</pub-id><pub-id pub-id-type="pmcid">PMC7164637</pub-id></element-citation></ref><ref id="b0100"><label>20</label><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name name-style="western"><surname>Coleman</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.V.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Massare</surname><given-names>M.</given-names></name><name name-style="western"><surname>Flyer</surname><given-names>D.C.</given-names></name><etal/></person-group><article-title>Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</article-title><source>Vaccine</source><volume>32</volume><year>2014</year><fpage>3169</fpage><lpage>3174</lpage><pub-id pub-id-type="pmid">24736006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2014.04.016</pub-id><pub-id pub-id-type="pmcid">PMC4058772</pub-id></element-citation></ref><ref id="b0105"><label>21</label><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name name-style="western"><surname>Fries</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Glenn</surname><given-names>G.M.</given-names></name></person-group><article-title>A recombinant viruslike particle influenza A (H7N9) vaccine</article-title><source>N Engl J Med</source><volume>369</volume><year>2013</year><fpage>2564</fpage><lpage>2566</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc1313186</pub-id><pub-id pub-id-type="pmid">24224560</pub-id></element-citation></ref><ref id="b0110"><label>22</label><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name name-style="western"><surname>Tamborrini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Geib</surname><given-names>N.</given-names></name><name name-style="western"><surname>Marrero-Nodarse</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jud</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>J.</given-names></name><name name-style="western"><surname>Aho</surname><given-names>C.</given-names></name><etal/></person-group><article-title>A synthetic virus-like particle streptococcal vaccine candidate using B-cell epitopes from the proline-rich region of pneumococcal surface protein A</article-title><source>Vaccines</source><volume>3</volume><year>2015</year><fpage>850</fpage><lpage>874</lpage><pub-id pub-id-type="pmid">26501327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines3040850</pub-id><pub-id pub-id-type="pmcid">PMC4693222</pub-id></element-citation></ref><ref id="b0115"><label>23</label><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Reicin</surname><given-names>A.S.</given-names></name></person-group><article-title>Discontinuation of VIOXX</article-title><source>The Lancet</source><volume>365</volume><year>2005</year><fpage>23</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(04)17652-6</pub-id><pub-id pub-id-type="pmid">15639669</pub-id></element-citation></ref><ref id="b0120"><label>24</label><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name name-style="western"><surname>Fromen</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Kai</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Ting</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>DeSimone</surname><given-names>J.M.</given-names></name></person-group><article-title>Controlled analysis of nanoparticle charge on mucosal and systemic antibody responses following pulmonary immunization</article-title><source>Proc Natl Acad Sci</source><volume>112</volume><year>2015</year><fpage>488</fpage><lpage>493</lpage><pub-id pub-id-type="pmid">25548169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1422923112</pub-id><pub-id pub-id-type="pmcid">PMC4299250</pub-id></element-citation></ref><ref id="b0125"><label>25</label><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Koo</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y.D.</given-names></name><etal/></person-group><article-title>Feasibility of placing a modified fully covered self-expandable metal stent above the papilla to minimize stent-induced bile duct injury in patients with refractory benign biliary strictures (with videos)</article-title><source>Gastrointest Endosc</source><volume>75</volume><year>2012</year><fpage>1080</fpage><lpage>1085</lpage><pub-id pub-id-type="pmid">22401821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gie.2012.01.016</pub-id></element-citation></ref><ref id="b0130"><label>26</label><element-citation publication-type="journal" id="h0130"><person-group person-group-type="author"><name name-style="western"><surname>Bachmann</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>G.T.</given-names></name></person-group><article-title>Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns</article-title><source>Nat Rev Immunol</source><volume>10</volume><year>2010</year><fpage>787</fpage><lpage>796</lpage><pub-id pub-id-type="pmid">20948547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri2868</pub-id></element-citation></ref><ref id="b0135"><label>27</label><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Berk</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Swartz</surname><given-names>M.A.</given-names></name></person-group><article-title>A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles</article-title><source>J Appl Physiol</source><volume>101</volume><year>2006</year><fpage>1162</fpage><lpage>1169</lpage><pub-id pub-id-type="pmid">16763103</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/japplphysiol.00389.2006</pub-id></element-citation></ref><ref id="b0140"><label>28</label><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name name-style="western"><surname>Heesters</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>M.C.</given-names></name></person-group><article-title>Follicular dendritic cells: dynamic antigen libraries</article-title><source>Nat Rev Immunol</source><volume>14</volume><year>2014</year><fpage>495</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">24948364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3689</pub-id></element-citation></ref><ref id="b0145"><label>29</label><element-citation publication-type="journal" id="h0145"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Suh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bershteyn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stephan</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses</article-title><source>Nat Mater</source><volume>10</volume><year>2011</year><fpage>243</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">21336265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmat2960</pub-id><pub-id pub-id-type="pmcid">PMC3077947</pub-id></element-citation></ref><ref id="b0150"><label>30</label><element-citation publication-type="journal" id="h0150"><person-group person-group-type="author"><name name-style="western"><surname>Hanson</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Crespo</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>W.</given-names></name><name name-style="western"><surname>Moynihan</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Szeto</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.H.</given-names></name><etal/></person-group><article-title>Nanoparticulate STING agonists are potent lymph node&#8211;targeted vaccine adjuvants</article-title><source>J Clin Investig</source><volume>125</volume><year>2015</year><fpage>2532</fpage><lpage>2546</lpage><pub-id pub-id-type="pmid">25938786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI79915</pub-id><pub-id pub-id-type="pmcid">PMC4497758</pub-id></element-citation></ref><ref id="b0155"><label>31</label><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name name-style="western"><surname>Nuhn</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vanparijs</surname><given-names>N.</given-names></name><name name-style="western"><surname>De Beuckelaer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lybaert</surname><given-names>L.</given-names></name><name name-style="western"><surname>Verstraete</surname><given-names>G.</given-names></name><name name-style="western"><surname>Deswarte</surname><given-names>K.</given-names></name><etal/></person-group><article-title>pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation</article-title><source>Proc Natl Acad Sci</source><volume>113</volume><year>2016</year><fpage>8098</fpage><lpage>8103</lpage><pub-id pub-id-type="pmid">27382168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1600816113</pub-id><pub-id pub-id-type="pmcid">PMC4961133</pub-id></element-citation></ref><ref id="b0160"><label>32</label><element-citation publication-type="journal" id="h0160"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C.-M.-J.</given-names></name><name name-style="western"><surname>Luk</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Copp</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Cell membrane-coated nanoparticles for anticancer vaccination and drug delivery</article-title><source>Nano Lett</source><volume>14</volume><year>2014</year><fpage>2181</fpage><lpage>2188</lpage><pub-id pub-id-type="pmid">24673373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/nl500618u</pub-id><pub-id pub-id-type="pmcid">PMC3985711</pub-id></element-citation></ref><ref id="b0165"><label>33</label><element-citation publication-type="journal" id="h0165"><person-group person-group-type="author"><name name-style="western"><surname>Kanekiyo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>C.-J.</given-names></name><name name-style="western"><surname>Yassine</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>McTamney</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Boyington</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Whittle</surname><given-names>J.R.R.</given-names></name><etal/></person-group><article-title>Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies</article-title><source>Nature</source><volume>499</volume><year>2013</year><fpage>102</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">23698367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature12202</pub-id><pub-id pub-id-type="pmcid">PMC8312026</pub-id></element-citation></ref><ref id="b0170"><label>34</label><element-citation publication-type="journal" id="h0170"><person-group person-group-type="author"><name name-style="western"><surname>Amanna</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Rau&#233;</surname><given-names>H.-P.</given-names></name><name name-style="western"><surname>Slifka</surname><given-names>M.K.</given-names></name></person-group><article-title>Development of a new hydrogen peroxide&#8211;based vaccine platform</article-title><source>Nat Med</source><volume>18</volume><year>2012</year><fpage>974</fpage><lpage>979</lpage><pub-id pub-id-type="pmid">22635006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.2763</pub-id><pub-id pub-id-type="pmcid">PMC3506259</pub-id></element-citation></ref><ref id="b0175"><label>35</label><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name name-style="western"><surname>Lesniak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fenaroli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Monopoli</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>&#197;berg</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Salvati</surname><given-names>A.</given-names></name></person-group><article-title>Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells</article-title><source>ACS Nano</source><volume>6</volume><year>2012</year><fpage>5845</fpage><lpage>5857</lpage><pub-id pub-id-type="pmid">22721453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/nn300223w</pub-id></element-citation></ref><ref id="b0180"><label>36</label><element-citation publication-type="journal" id="h0180"><person-group person-group-type="author"><name name-style="western"><surname>Walkey</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Song</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>D.W.H.</given-names></name><etal/></person-group><article-title>Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles</article-title><source>ACS Nano</source><volume>8</volume><year>2014</year><fpage>2439</fpage><lpage>2455</lpage><pub-id pub-id-type="pmid">24517450</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/nn406018q</pub-id></element-citation></ref><ref id="b0185"><label>37</label><element-citation publication-type="journal" id="h0185"><person-group person-group-type="author"><name name-style="western"><surname>Walkey</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>W.C.</given-names></name></person-group><article-title>Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment</article-title><source>Chem Soc Rev</source><volume>41</volume><year>2012</year><fpage>2780</fpage><lpage>2799</lpage><pub-id pub-id-type="pmid">22086677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c1cs15233e</pub-id></element-citation></ref><ref id="b0190"><label>38</label><element-citation publication-type="journal" id="h0190"><person-group person-group-type="author"><name name-style="western"><surname>Nel</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>M&#228;dler</surname><given-names>L.</given-names></name><name name-style="western"><surname>Velegol</surname><given-names>D.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hoek</surname><given-names>E.M.V.</given-names></name><name name-style="western"><surname>Somasundaran</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Understanding biophysicochemical interactions at the nano&#8211;bio interface</article-title><source>Nat Mater</source><volume>8</volume><year>2009</year><fpage>543</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">19525947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmat2442</pub-id></element-citation></ref><ref id="b0195"><label>39</label><element-citation publication-type="journal" id="h0195"><person-group person-group-type="author"><name name-style="western"><surname>Tenzer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Docter</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kuharev</surname><given-names>J.</given-names></name><name name-style="western"><surname>Musyanovych</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fetz</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hecht</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology</article-title><source>Nat Nanotechnol</source><volume>8</volume><year>2013</year><fpage>772</fpage><lpage>781</lpage><pub-id pub-id-type="pmid">24056901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nnano.2013.181</pub-id></element-citation></ref><ref id="b0200"><label>40</label><element-citation publication-type="journal" id="h0200"><person-group person-group-type="author"><name name-style="western"><surname>Sch&#246;ttler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>G.</given-names></name><name name-style="western"><surname>Winzen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Steinbach</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mohr</surname><given-names>K.</given-names></name><name name-style="western"><surname>Landfester</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers</article-title><source>Nat Nanotechnol</source><volume>11</volume><year>2016</year><fpage>372</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">26878141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nnano.2015.330</pub-id></element-citation></ref><ref id="b0205"><label>41</label><element-citation publication-type="journal" id="h0205"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Z.S.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Synthetic virus-like particles prepared via protein corona formation enable effective vaccination in an avian model of coronavirus infection</article-title><source>Biomaterials</source><volume>106</volume><year>2016</year><fpage>111</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">27552321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2016.08.018</pub-id><pub-id pub-id-type="pmcid">PMC7112462</pub-id></element-citation></ref><ref id="b0210"><label>42</label><element-citation publication-type="journal" id="h0210"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takami</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Deo</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Park</surname><given-names>E.Y.</given-names></name></person-group><article-title>Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells</article-title><source>J Biotechnol</source><volume>306</volume><year>2019</year><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">31614169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbiotec.2019.10.007</pub-id><pub-id pub-id-type="pmcid">PMC7114102</pub-id></element-citation></ref><ref id="b0215"><label>43</label><element-citation publication-type="journal" id="h0215"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B.-J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>The spike protein of SARS-CoV&#8212;a target for vaccine and therapeutic development</article-title><source>Nat Rev Microbiol</source><volume>7</volume><year>2009</year><fpage>226</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">19198616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrmicro2090</pub-id><pub-id pub-id-type="pmcid">PMC2750777</pub-id></element-citation></ref><ref id="b0220"><label>44</label><element-citation publication-type="journal" id="h0220"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><etal/></person-group><article-title>A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines</article-title><source>PLoS ONE</source><volume>8</volume><year>2013</year><fpage>e81587</fpage><pub-id pub-id-type="pmid">24324708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0081587</pub-id><pub-id pub-id-type="pmcid">PMC3852489</pub-id></element-citation></ref><ref id="b0225"><label>45</label><element-citation publication-type="journal" id="h0225"><person-group person-group-type="author"><name name-style="western"><surname>de Haan</surname><given-names>C.A.M.</given-names></name><name name-style="western"><surname>Masters</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rottier</surname><given-names>P.J.M.</given-names></name></person-group><article-title>The group-specific murine coronavirus genes are not essential, but their deletion, by reverse genetics, is attenuating in the natural host</article-title><source>Virology</source><volume>296</volume><year>2002</year><fpage>177</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">12036329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/viro.2002.1412</pub-id><pub-id pub-id-type="pmcid">PMC7133727</pub-id></element-citation></ref><ref id="b0230"><label>46</label><element-citation publication-type="journal" id="h0230"><person-group person-group-type="author"><name name-style="western"><surname>Haijema</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Volders</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rottier</surname><given-names>P.J.M.</given-names></name></person-group><article-title>Live, attenuated coronavirus vaccines through the directed deletion of group-specific genes provide protection against feline infectious peritonitis</article-title><source>J Virol</source><volume>78</volume><year>2004</year><fpage>3863</fpage><lpage>3871</lpage><pub-id pub-id-type="pmid">15047802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.78.8.3863-3871.2004</pub-id><pub-id pub-id-type="pmcid">PMC374255</pub-id></element-citation></ref><ref id="b0235"><label>47</label><element-citation publication-type="journal" id="h0235"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>MERS-CoV spike protein: a key target for antivirals</article-title><source>Expert Opin Therapeut Targets</source><volume>21</volume><year>2017</year><fpage>131</fpage><lpage>143</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14728222.2017.1271415</pub-id><pub-id pub-id-type="pmcid">PMC5457961</pub-id><pub-id pub-id-type="pmid">27936982</pub-id></element-citation></ref><ref id="b0240"><label>48</label><element-citation publication-type="journal" id="h0240"><person-group person-group-type="author"><name name-style="western"><surname>Corti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pedotti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Simonelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Agnihothram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fett</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus</article-title><source>Proc Natl Acad Sci</source><volume>112</volume><year>2015</year><fpage>10473</fpage><lpage>10478</lpage><pub-id pub-id-type="pmid">26216974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1510199112</pub-id><pub-id pub-id-type="pmcid">PMC4547275</pub-id></element-citation></ref><ref id="b0245"><label>49</label><element-citation publication-type="journal" id="h0245"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.-T.-K.</given-names></name><etal/></person-group><article-title>Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments&#8212;the importance of immunofocusing in subunit vaccine design</article-title><source>Vaccine</source><volume>32</volume><year>2014</year><fpage>6170</fpage><lpage>6176</lpage><pub-id pub-id-type="pmid">25240756</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2014.08.086</pub-id><pub-id pub-id-type="pmcid">PMC4194190</pub-id></element-citation></ref><ref id="b0250"><label>50</label><element-citation publication-type="journal" id="h0250"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.-T.-K.</given-names></name><etal/></person-group><article-title>Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines</article-title><source>Vaccine</source><volume>32</volume><year>2014</year><fpage>2100</fpage><lpage>2108</lpage><pub-id pub-id-type="pmid">24560617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2014.02.004</pub-id><pub-id pub-id-type="pmcid">PMC4194189</pub-id></element-citation></ref><ref id="b0255"><label>51</label><element-citation publication-type="journal" id="h0255"><person-group person-group-type="author"><name name-style="western"><surname>Ying</surname><given-names>T.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Prabakaran</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies</article-title><source>J Virol</source><volume>88</volume><year>2014</year><fpage>7796</fpage><lpage>7805</lpage><pub-id pub-id-type="pmid">24789777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00912-14</pub-id><pub-id pub-id-type="pmcid">PMC4097770</pub-id></element-citation></ref><ref id="b0260"><label>52</label><element-citation publication-type="journal" id="h0260"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Poon</surname><given-names>K.-M.-V.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein</article-title><source>Sci Translat Med</source><volume>6</volume><year>2014</year><comment>234ra59-ra59</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.3008140</pub-id><pub-id pub-id-type="pmid">24778414</pub-id></element-citation></ref><ref id="b0265"><label>53</label><element-citation publication-type="journal" id="h0265"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein</article-title><source>J Virol</source><volume>88</volume><year>2014</year><fpage>7045</fpage><lpage>7053</lpage><pub-id pub-id-type="pmid">24719424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00433-14</pub-id><pub-id pub-id-type="pmcid">PMC4054355</pub-id></element-citation></ref><ref id="b0270"><label>54</label><element-citation publication-type="journal" id="h0270"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chakraborti</surname><given-names>S.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sheahan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies</article-title><source>Proc Natl Acad Sci</source><volume>104</volume><year>2007</year><fpage>12123</fpage><lpage>12128</lpage><pub-id pub-id-type="pmid">17620608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0701000104</pub-id><pub-id pub-id-type="pmcid">PMC1924550</pub-id></element-citation></ref><ref id="b0275"><label>55</label><element-citation publication-type="journal" id="h0275"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>X.-C.</given-names></name><name name-style="western"><surname>Agnihothram</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Stanhope</surname><given-names>J.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>E.C.</given-names></name><etal/></person-group><article-title>Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution</article-title><source>Proc Natl Acad Sci</source><volume>111</volume><year>2014</year><fpage>E2018</fpage><lpage>E2026</lpage><pub-id pub-id-type="pmid">24778221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1402074111</pub-id><pub-id pub-id-type="pmcid">PMC4024880</pub-id></element-citation></ref><ref id="b0280"><label>56</label><element-citation publication-type="journal" id="h0280"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.-Y.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>D.-W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.-L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Heterologous prime&#8211;boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus</article-title><source>Vaccine</source><volume>36</volume><year>2018</year><fpage>3468</fpage><lpage>3476</lpage><pub-id pub-id-type="pmid">29739720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2018.04.082</pub-id><pub-id pub-id-type="pmcid">PMC7115429</pub-id></element-citation></ref><ref id="b0285"><label>57</label><element-citation publication-type="journal" id="h0285"><person-group person-group-type="author"><name name-style="western"><surname>Lynn</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Laga</surname><given-names>R.</given-names></name><name name-style="western"><surname>Darrah</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Ishizuka</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Balaci</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Dulcey</surname><given-names>A.E.</given-names></name><etal/></person-group><article-title>In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity</article-title><source>Nat Biotechnol</source><volume>33</volume><year>2015</year><fpage>1201</fpage><pub-id pub-id-type="pmid">26501954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.3371</pub-id><pub-id pub-id-type="pmcid">PMC5842712</pub-id></element-citation></ref><ref id="b0290"><label>58</label><element-citation publication-type="journal" id="h0290"><person-group person-group-type="author"><name name-style="western"><surname>Ilyinskii</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>O&#8217;Neil</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Browning</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Pittet</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Altreuter</surname><given-names>D.H.</given-names></name><etal/></person-group><article-title>Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release</article-title><source>Vaccine</source><volume>32</volume><year>2014</year><fpage>2882</fpage><lpage>2895</lpage><pub-id pub-id-type="pmid">24593999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2014.02.027</pub-id><pub-id pub-id-type="pmcid">PMC4059049</pub-id></element-citation></ref><ref id="b0295"><label>59</label><element-citation publication-type="journal" id="h0295"><person-group person-group-type="author"><name name-style="western"><surname>Goodwin</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>Investigation of phosphorylated adjuvants co-encapsulated with a model cancer peptide antigen for the treatment of colorectal cancer and liver metastasis</article-title><source>Vaccine</source><volume>35</volume><year>2017</year><fpage>2550</fpage><lpage>2557</lpage><pub-id pub-id-type="pmid">28385609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2017.03.067</pub-id><pub-id pub-id-type="pmcid">PMC5448460</pub-id></element-citation></ref><ref id="b0300"><label>60</label><element-citation publication-type="journal" id="h0300"><person-group person-group-type="author"><name name-style="western"><surname>Koshy</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Graveline</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Mooney</surname><given-names>D.J.</given-names></name></person-group><article-title>Liposomal delivery enhances immune activation by STING agonists for cancer immunotherapy</article-title><source>Adv Biosyst</source><volume>1</volume><year>2017</year><fpage>1600013</fpage><pub-id pub-id-type="pmid">30258983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adbi.201600013</pub-id><pub-id pub-id-type="pmcid">PMC6152940</pub-id></element-citation></ref><ref id="b0305"><label>61</label><element-citation publication-type="journal" id="h0305"><person-group person-group-type="author"><name name-style="western"><surname>Collier</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Junkins</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Gallovic</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Macintyre</surname><given-names>A.N.</given-names></name><etal/></person-group><article-title>Acetalated dextran microparticles for codelivery of STING and TLR7/8 agonists</article-title><source>Mol Pharm</source><volume>15</volume><year>2018</year><fpage>4933</fpage><lpage>4946</lpage><pub-id pub-id-type="pmid">30281314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.8b00579</pub-id><pub-id pub-id-type="pmcid">PMC6261357</pub-id></element-citation></ref><ref id="b0310"><label>62</label><element-citation publication-type="journal" id="h0310"><person-group person-group-type="author"><name name-style="western"><surname>Junkins</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Gallovic</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Collier</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Watkins-Schulz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>N.</given-names></name><etal/></person-group><article-title>A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination</article-title><source>J Control Release</source><volume>270</volume><year>2018</year><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">29170142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2017.11.030</pub-id><pub-id pub-id-type="pmcid">PMC5808851</pub-id></element-citation></ref><ref id="b0315"><label>63</label><element-citation publication-type="journal" id="h0315"><person-group person-group-type="author"><name name-style="western"><surname>Aroh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dobbs</surname><given-names>N.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Innate immune activation by cGMP-AMP nanoparticles leads to potent and long-acting antiretroviral response against HIV-1</article-title><source>J Immunol</source><volume>199</volume><year>2017</year><fpage>3840</fpage><lpage>3848</lpage><pub-id pub-id-type="pmid">29084836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1700972</pub-id><pub-id pub-id-type="pmcid">PMC5916791</pub-id></element-citation></ref><ref id="b0320"><label>64</label><element-citation publication-type="journal" id="h0320"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Sen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sunshine</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Pardoll</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Green</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.J.</given-names></name></person-group><article-title>Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy</article-title><source>Nanomed Nanotechnol Biol Med</source><volume>14</volume><year>2018</year><fpage>237</fpage><lpage>246</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nano.2017.10.013</pub-id><pub-id pub-id-type="pmcid">PMC6035751</pub-id><pub-id pub-id-type="pmid">29127039</pub-id></element-citation></ref><ref id="b0325"><label>65</label><element-citation publication-type="journal" id="h0325"><person-group person-group-type="author"><name name-style="western"><surname>Galarza</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Latham</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cupo</surname><given-names>A.</given-names></name></person-group><article-title>Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge</article-title><source>Viral Immunol</source><volume>18</volume><year>2005</year><fpage>244</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">15802970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/vim.2005.18.244</pub-id></element-citation></ref><ref id="b0330"><label>66</label><element-citation publication-type="journal" id="h0330"><person-group person-group-type="author"><name name-style="western"><surname>Gregory</surname><given-names>A.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Titball</surname><given-names>R.</given-names></name></person-group><article-title>Vaccine delivery using nanoparticles</article-title><source>Front Cell Infect Microbiol</source><volume>3</volume><year>2013</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2013.00013</pub-id><pub-id pub-id-type="pmcid">PMC3607064</pub-id><pub-id pub-id-type="pmid">23532930</pub-id></element-citation></ref><ref id="b0335"><label>67</label><element-citation publication-type="journal" id="h0335"><person-group person-group-type="author"><name name-style="western"><surname>Jagu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kwak</surname><given-names>K.</given-names></name><name name-style="western"><surname>Karanam</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huh</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Damotharan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chivukula</surname><given-names>S.V.</given-names></name><etal/></person-group><article-title>Optimization of multimeric human papillomavirus L2 vaccines</article-title><source>PLoS ONE</source><volume>8</volume><year>2013</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0055538</pub-id><pub-id pub-id-type="pmcid">PMC3561222</pub-id><pub-id pub-id-type="pmid">23383218</pub-id></element-citation></ref><ref id="b0340"><label>68</label><element-citation publication-type="journal" id="h0340"><person-group person-group-type="author"><name name-style="western"><surname>Almeida</surname><given-names>J.P.M.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Figueroa</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Foster</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Drezek</surname><given-names>R.A.</given-names></name></person-group><article-title>In vivo gold nanoparticle delivery of peptide vaccine induces anti-tumor immune response in prophylactic and therapeutic tumor models</article-title><source>Small</source><volume>11</volume><year>2015</year><fpage>1453</fpage><lpage>1459</lpage><pub-id pub-id-type="pmid">25354691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.201402179</pub-id><pub-id pub-id-type="pmcid">PMC4373976</pub-id></element-citation></ref><ref id="b0345"><label>69</label><element-citation publication-type="journal" id="h0345"><person-group person-group-type="author"><name name-style="western"><surname>Charlton Hume</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Vidigal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Carrondo</surname><given-names>M.J.T.</given-names></name><name name-style="western"><surname>Middelberg</surname><given-names>A.P.J.</given-names></name><name name-style="western"><surname>Rold&#227;o</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lua</surname><given-names>L.H.L.</given-names></name></person-group><article-title>Synthetic biology for bioengineering virus-like particle vaccines</article-title><source>Biotechnol Bioeng</source><volume>116</volume><year>2019</year><fpage>919</fpage><lpage>935</lpage><pub-id pub-id-type="pmid">30597533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bit.26890</pub-id><pub-id pub-id-type="pmcid">PMC7161758</pub-id></element-citation></ref><ref id="b0350"><label>70</label><element-citation publication-type="journal" id="h0350"><person-group person-group-type="author"><name name-style="western"><surname>Rohovie</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Nagasawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Swartz</surname><given-names>J.R.</given-names></name></person-group><article-title>Virus-like particles: Next-generation nanoparticles for targeted therapeutic delivery</article-title><source>Bioeng Transl Med</source><volume>2</volume><year>2017</year><fpage>43</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">29313023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/btm2.10049</pub-id><pub-id pub-id-type="pmcid">PMC5689521</pub-id></element-citation></ref><ref id="b0355"><label>71</label><element-citation publication-type="journal" id="h0355"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Zare</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Moses</surname><given-names>M.A.</given-names></name></person-group><article-title>Nanomaterial preparation by extrusion through nanoporous membranes</article-title><source>Small</source><volume>14</volume><year>2018</year><fpage>1703493</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.201703493</pub-id><pub-id pub-id-type="pmid">29468837</pub-id></element-citation></ref><ref id="b0360"><label>72</label><element-citation publication-type="journal" id="h0360"><person-group person-group-type="author"><name name-style="western"><surname>Mi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name></person-group><article-title>Bio-inspired virus-like nanovesicle for effective vaccination</article-title><source>Hum Vacc Immunotherapeut</source><volume>12</volume><year>2016</year><fpage>2090</fpage><lpage>2091</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2016.1157244</pub-id><pub-id pub-id-type="pmcid">PMC4994763</pub-id><pub-id pub-id-type="pmid">27141919</pub-id></element-citation></ref><ref id="b0365"><label>73</label><element-citation publication-type="journal" id="h0365"><person-group person-group-type="author"><name name-style="western"><surname>Murata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lechmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gunji</surname><given-names>T.</given-names></name><name name-style="western"><surname>Alter</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>T.J.</given-names></name></person-group><article-title>Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection</article-title><source>Proc Natl Acad Sci</source><volume>100</volume><year>2003</year><fpage>6753</fpage><lpage>6758</lpage><pub-id pub-id-type="pmid">12748380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1131929100</pub-id><pub-id pub-id-type="pmcid">PMC164519</pub-id></element-citation></ref><ref id="b0370"><label>74</label><element-citation publication-type="journal" id="h0370"><person-group person-group-type="author"><name name-style="western"><surname>Quan</surname><given-names>F.-S.</given-names></name><name name-style="western"><surname>Compans</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.-M.</given-names></name></person-group><article-title>Induction of heterosubtypic immunity to influenza virus by intranasal immunization</article-title><source>J Virol</source><volume>82</volume><year>2008</year><fpage>1350</fpage><lpage>1359</lpage><pub-id pub-id-type="pmid">18032492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01615-07</pub-id><pub-id pub-id-type="pmcid">PMC2224423</pub-id></element-citation></ref><ref id="b0375"><label>75</label><element-citation publication-type="journal" id="h0375"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Modjarrad</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Evaluation of candidate vaccine approaches for MERS-CoV</article-title><source>Nat Commun</source><volume>6</volume><year>2015</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms8712</pub-id><pub-id pub-id-type="pmcid">PMC4525294</pub-id><pub-id pub-id-type="pmid">26218507</pub-id></element-citation></ref><ref id="b0380"><label>76</label><element-citation publication-type="journal" id="h0380"><person-group person-group-type="author"><name name-style="western"><surname>Coleman</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Venkataraman</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.V.</given-names></name><name name-style="western"><surname>Glenn</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Flyer</surname><given-names>D.C.</given-names></name><etal/></person-group><article-title>MERS-CoV spike nanoparticles protect mice from MERS-CoV infection</article-title><source>Vaccine</source><volume>35</volume><year>2017</year><fpage>1586</fpage><lpage>1589</lpage><pub-id pub-id-type="pmid">28237499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2017.02.012</pub-id><pub-id pub-id-type="pmcid">PMC5423355</pub-id></element-citation></ref><ref id="b0385"><label>77</label><element-citation publication-type="journal" id="h0385"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice</article-title><source>Antiviral Res</source><volume>140</volume><year>2017</year><fpage>55</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">28040513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2016.12.019</pub-id><pub-id pub-id-type="pmcid">PMC7113847</pub-id></element-citation></ref><ref id="b0390"><label>78</label><element-citation publication-type="journal" id="h0390"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques</article-title><source>Oncotarget</source><volume>8</volume><year>2017</year><fpage>12686</fpage><pub-id pub-id-type="pmid">27050368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.8475</pub-id><pub-id pub-id-type="pmcid">PMC5355045</pub-id></element-citation></ref><ref id="b0395"><label>79</label><element-citation publication-type="journal" id="h0395"><person-group person-group-type="author"><name name-style="western"><surname>Luke</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Channappanavar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo</article-title><source>Sci Transl Med</source><volume>8</volume><year>2016</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aaf1061</pub-id><pub-id pub-id-type="pmid">26888429</pub-id></element-citation></ref><ref id="b0400"><label>80</label><element-citation publication-type="journal" id="h0400"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y.-S.</given-names></name><name name-style="western"><surname>Son</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Chaperna-mediated assembly of ferritin-based Middle East respiratory syndrome-coronavirus nanoparticles</article-title><source>Front Immunol</source><volume>9</volume><year>2018</year><fpage>1093</fpage><pub-id pub-id-type="pmid">29868035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.01093</pub-id><pub-id pub-id-type="pmcid">PMC5966535</pub-id></element-citation></ref><ref id="b0405"><label>81</label><element-citation publication-type="journal" id="h0405"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Virus-mimetic nanovesicles as a versatile antigen-delivery system</article-title><source>Proc Natl Acad Sci</source><volume>112</volume><year>2015</year><fpage>E6129</fpage><lpage>E6138</lpage><pub-id pub-id-type="pmid">26504197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1505799112</pub-id><pub-id pub-id-type="pmcid">PMC4653155</pub-id></element-citation></ref><ref id="b0410"><label>82</label><element-citation publication-type="journal" id="h0410"><person-group person-group-type="author"><name name-style="western"><surname>Gangadaran</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Rajendran</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Kalimuthu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Son</surname><given-names>S.H.</given-names></name><etal/></person-group><article-title>In vivo non-invasive imaging of radio-labeled exosome-mimetics derived from red blood cells in mice</article-title><source>Front Pharmacol</source><volume>9</volume><year>2018</year><fpage>817</fpage><pub-id pub-id-type="pmid">30104975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2018.00817</pub-id><pub-id pub-id-type="pmcid">PMC6078013</pub-id></element-citation></ref><ref id="b0415"><label>83</label><element-citation publication-type="journal" id="h0415"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>O.Y.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>D.-S.</given-names></name><name name-style="western"><surname>Roh</surname><given-names>T.-Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors</article-title><source>ACS Nano</source><volume>7</volume><year>2013</year><fpage>7698</fpage><lpage>7710</lpage><pub-id pub-id-type="pmid">24004438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/nn402232g</pub-id></element-citation></ref><ref id="b0420"><label>84</label><element-citation publication-type="journal" id="h0420"><person-group person-group-type="author"><name name-style="western"><surname>Ong</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>K.L.</given-names></name></person-group><article-title>Virus like particles as a platform for cancer vaccine development</article-title><source>PeerJ</source><volume>5</volume><year>2017</year><fpage>e4053</fpage><pub-id pub-id-type="pmid">29158984</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7717/peerj.4053</pub-id><pub-id pub-id-type="pmcid">PMC5694210</pub-id></element-citation></ref><ref id="b0425"><label>85</label><element-citation publication-type="journal" id="h0425"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name></person-group><article-title>Significant spike-specific IgG and neutralizing antibodies in mice induced by a novel chimeric virus-like particle vaccine candidate for middle east respiratory syndrome coronavirus</article-title><source>Virol Sin</source><volume>33</volume><year>2018</year><fpage>453</fpage><lpage>455</lpage><pub-id pub-id-type="pmid">30374826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12250-018-0064-8</pub-id><pub-id pub-id-type="pmcid">PMC6235757</pub-id></element-citation></ref><ref id="b0430"><label>86</label><element-citation publication-type="journal" id="h0430"><person-group person-group-type="author"><name name-style="western"><surname>Wirblich</surname><given-names>C.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Kurup</surname><given-names>D.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Bernbaum</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Jahrling</surname><given-names>P.B.</given-names></name><etal/></person-group><article-title>A safe, efficient dual-use vaccine for humans and animals against MERS-CoV and rabies virus</article-title><source>J Virol</source><year>2016</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02040-16</pub-id><pub-id pub-id-type="pmcid">PMC5215356</pub-id><pub-id pub-id-type="pmid">27807241</pub-id></element-citation></ref><ref id="b0435"><label>87</label><element-citation publication-type="journal" id="h0435"><person-group person-group-type="author"><name name-style="western"><surname>Channappanavar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Meyerholz</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Protective effect of intranasal regimens containing peptidic middle east respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection</article-title><source>J Infect Dis</source><volume>212</volume><year>2015</year><fpage>1894</fpage><lpage>1903</lpage><pub-id pub-id-type="pmid">26164863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiv325</pub-id><pub-id pub-id-type="pmcid">PMC4655857</pub-id></element-citation></ref><ref id="b0440"><label>88</label><element-citation publication-type="journal" id="h0440"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein</article-title><source>Cell Res</source><volume>25</volume><year>2015</year><fpage>1237</fpage><lpage>1249</lpage><pub-id pub-id-type="pmid">26391698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cr.2015.113</pub-id><pub-id pub-id-type="pmcid">PMC4650419</pub-id></element-citation></ref><ref id="b0445"><label>89</label><element-citation publication-type="journal" id="h0445"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Lysosomal proteases are a determinant of coronavirus tropism</article-title><source>J Virol</source><volume>92</volume><year>2018</year><fpage>e01504</fpage><lpage>e1518</lpage><pub-id pub-id-type="pmid">30258004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01504-18</pub-id><pub-id pub-id-type="pmcid">PMC6258935</pub-id></element-citation></ref><ref id="b0450"><label>90</label><element-citation publication-type="journal" id="h0450"><person-group person-group-type="author"><name name-style="western"><surname>Millet</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Whittaker</surname><given-names>G.R.</given-names></name></person-group><article-title>Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein</article-title><source>Proc Natl Acad Sci</source><volume>111</volume><year>2014</year><fpage>15214</fpage><lpage>15219</lpage><pub-id pub-id-type="pmid">25288733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1407087111</pub-id><pub-id pub-id-type="pmcid">PMC4210292</pub-id></element-citation></ref><ref id="b0455"><label>91</label><element-citation publication-type="journal" id="h0455"><person-group person-group-type="author"><name name-style="western"><surname>Shirato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kawase</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matsuyama</surname><given-names>S.</given-names></name></person-group><article-title>Middle east respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2</article-title><source>J Virol</source><volume>87</volume><year>2013</year><fpage>12552</fpage><pub-id pub-id-type="pmid">24027332</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01890-13</pub-id><pub-id pub-id-type="pmcid">PMC3838146</pub-id></element-citation></ref><ref id="b0460"><label>92</label><element-citation publication-type="journal" id="h0460"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hulswit</surname><given-names>R.J.G.</given-names></name><name name-style="western"><surname>Widjaja</surname><given-names>I.</given-names></name><name name-style="western"><surname>Raj</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>McBride</surname><given-names>R.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein</article-title><source>Proc Natl Acad Sci</source><volume>114</volume><year>2017</year><fpage>E8508</fpage><lpage>E8517</lpage><pub-id pub-id-type="pmid">28923942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1712592114</pub-id><pub-id pub-id-type="pmcid">PMC5635925</pub-id></element-citation></ref><ref id="b0465"><label>93</label><element-citation publication-type="journal" id="h0465"><person-group person-group-type="author"><name name-style="western"><surname>de Wilde</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Raj</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Oudshoorn</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bestebroer</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>van Nieuwkoop</surname><given-names>S.</given-names></name><name name-style="western"><surname>Limpens</surname><given-names>R.W.A.L.</given-names></name><etal/></person-group><article-title>MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-&#945; treatment</article-title><source>J Gen Virol</source><volume>94</volume><year>2013</year><fpage>1749</fpage><lpage>1760</lpage><pub-id pub-id-type="pmid">23620378</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/vir.0.052910-0</pub-id><pub-id pub-id-type="pmcid">PMC3749523</pub-id></element-citation></ref><ref id="b0470"><label>94</label><element-citation publication-type="journal" id="h0470"><person-group person-group-type="author"><name name-style="western"><surname>Falzarano</surname><given-names>D.</given-names></name><name name-style="western"><surname>de Wit</surname><given-names>E.</given-names></name><name name-style="western"><surname>Martellaro</surname><given-names>C.</given-names></name><name name-style="western"><surname>Callison</surname><given-names>J.</given-names></name><name name-style="western"><surname>Munster</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>H.</given-names></name></person-group><article-title>Inhibition of novel &#946; coronavirus replication by a combination of interferon-&#945;2b and ribavirin</article-title><source>Sci Rep</source><volume>3</volume><year>2013</year><fpage>1686</fpage><pub-id pub-id-type="pmid">23594967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep01686</pub-id><pub-id pub-id-type="pmcid">PMC3629412</pub-id></element-citation></ref><ref id="b0475"><label>95</label><element-citation publication-type="journal" id="h0475"><person-group person-group-type="author"><name name-style="western"><surname>Neuhaus</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chichester</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Ebensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hartman</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Shoji</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung</article-title><source>Vaccine</source><volume>32</volume><year>2014</year><fpage>3216</fpage><lpage>3222</lpage><pub-id pub-id-type="pmid">24731807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2014.04.011</pub-id></element-citation></ref><ref id="b0480"><label>96</label><element-citation publication-type="journal" id="h0480"><person-group person-group-type="author"><name name-style="western"><surname>Segura-Cerda</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>de Jes&#250;s</surname><given-names>A.-S&#225;nchez M.</given-names></name><name name-style="western"><surname>Marquina-Castillo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mata-Espinoza</surname><given-names>D.</given-names></name><name name-style="western"><surname>Barrios-Pay&#225;n</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vega-Dom&#237;nguez</surname><given-names>P.J.</given-names></name><etal/></person-group><article-title>Immune response elicited by two rBCG strains devoid of genes involved in c-di-GMP metabolism affect protection versus challenge with M. tuberculosis strains of different virulence</article-title><source>Vaccine</source><volume>36</volume><year>2018</year><fpage>2069</fpage><lpage>2078</lpage><pub-id pub-id-type="pmid">29550192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2018.03.014</pub-id></element-citation></ref><ref id="b0485"><label>97</label><element-citation publication-type="journal" id="h0485"><person-group person-group-type="author"><name name-style="western"><surname>Sivick</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Desbien</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Glickman</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Reiner</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Corrales</surname><given-names>L.</given-names></name><name name-style="western"><surname>Surh</surname><given-names>N.H.</given-names></name><etal/></person-group><article-title>Magnitude of therapeutic STING activation determines CD8+ T cell-mediated anti-tumor immunity</article-title><source>Cell Rep</source><volume>25</volume><year>2018</year><comment>3074&#8211;85 e5</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2018.11.047</pub-id><pub-id pub-id-type="pmid">30540940</pub-id></element-citation></ref><ref id="b0490"><label>98</label><element-citation publication-type="journal" id="h0490"><person-group person-group-type="author"><name name-style="western"><surname>Tzeng</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kauke</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Moynihan</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Opel</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>N.J.</given-names></name><etal/></person-group><article-title>Temporally programmed CD8&#945;+ DC activation enhances combination cancer immunotherapy</article-title><source>Cell Rep</source><volume>17</volume><year>2016</year><fpage>2503</fpage><lpage>2511</lpage><pub-id pub-id-type="pmid">27926855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2016.11.020</pub-id><pub-id pub-id-type="pmcid">PMC5204262</pub-id></element-citation></ref><ref id="b0495"><label>99</label><element-citation publication-type="journal" id="h0495"><person-group person-group-type="author"><name name-style="western"><surname>Moreira-Teixeira</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mayer-Barber</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sher</surname><given-names>A.</given-names></name><name name-style="western"><surname>O&#8217;Garra</surname><given-names>A.</given-names></name></person-group><article-title>Type I interferons in tuberculosis: Foe and occasionally friend</article-title><source>J Exp Med</source><volume>215</volume><year>2018</year><fpage>1273</fpage><lpage>1285</lpage><pub-id pub-id-type="pmid">29666166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20180325</pub-id><pub-id pub-id-type="pmcid">PMC5940272</pub-id></element-citation></ref><ref id="b0500"><label>100</label><element-citation publication-type="journal" id="h0500"><person-group person-group-type="author"><name name-style="western"><surname>Boxx</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>G.</given-names></name></person-group><article-title>The roles of type I interferon in bacterial infection</article-title><source>Cell Host Microbe</source><volume>19</volume><year>2016</year><fpage>760</fpage><lpage>769</lpage><pub-id pub-id-type="pmid">27281568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2016.05.016</pub-id><pub-id pub-id-type="pmcid">PMC5847370</pub-id></element-citation></ref><ref id="b0505"><label>101</label><element-citation publication-type="journal" id="h0505"><person-group person-group-type="author"><name name-style="western"><surname>Stifter</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>C.G.</given-names></name></person-group><article-title>Interfering with immunity: detrimental role of type I IFNs during infection</article-title><source>J Immunol</source><volume>194</volume><year>2015</year><fpage>2455</fpage><lpage>2465</lpage><pub-id pub-id-type="pmid">25747907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1402794</pub-id></element-citation></ref><ref id="b0510"><label>102</label><element-citation publication-type="journal" id="h0510"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.-D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.J.</given-names></name></person-group><article-title>Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects</article-title><source>Science</source><volume>341</volume><year>2013</year><fpage>1390</fpage><lpage>1394</lpage><pub-id pub-id-type="pmid">23989956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1244040</pub-id><pub-id pub-id-type="pmcid">PMC3863637</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>